RGNX Share Price Performance
US$8.33
-4.18 (-33.41%)
73.5% undervalued intrinsic discount
US$31.42
Fair Value
Price US$8.33
AnalystConsensusTarget US$31.42
Fair ValueUS$31.42
Share PriceUS$8.33
73.5% undervalued intrinsic discount
RGNX Community Narratives
AN
Fair Value US$31.42 73.5% undervalued intrinsic discount
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
RGNX Community Fair Values
- AN
Consensus Narrative from 12 AnalystsFDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Key Takeaways Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments. Advancements in pivotal trials and robust financing options position the company for long-term revenue and market share expansion.US$31.42FV73.5% undervalued intrinsic discount29.19%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative5users have followed this narrative12 days ago author updated this narrative
Recent RGNX News & Updates
No updates
REGENXBIO Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- -3.13
- Gross Margin
- 80.24%
- Net Profit Margin
- -100.62%
- Debt/Equity Ratio
- 19.6%
REGENXBIO Inc. Competitors
About RGNX
- Founded
- 2008
- Employees
- 353
- CEO
- WebsiteView website
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading